Research programme: carbacephem antibacterials - Blanca Pharmaceuticals
Alternative Names: 3-Heteroarylthio carbacephems - Blanca Pharmaceuticals; BP-101 - Blanca Pharmaceuticals; BP-102 - Blanca Pharmaceuticals; BP-103 - Blanca Pharmaceuticals; BP-104 - Blanca PharmaceuticalsLatest Information Update: 16 Jul 2016
At a glance
- Originator Blanca Pharmaceuticals
- Developer NAEJA Pharmaceutical; SRI International; Ulysses Pharmaceuticals
- Class
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Canada (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in Canada (Parenteral)